Rare Germline Variants in Chordoma-Related Genes and Chordoma Susceptibility.
WES
WGS
cancer susceptibility
chordoma
germline variants
notochord development
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
30 May 2021
30 May 2021
Historique:
received:
27
04
2021
revised:
20
05
2021
accepted:
24
05
2021
entrez:
2
6
2021
pubmed:
3
6
2021
medline:
3
6
2021
Statut:
epublish
Résumé
Chordoma is a rare bone cancer with an unknown etiology. TBXT is the only chordoma susceptibility gene identified to date; germline single nucleotide variants and copy number variants in TBXT have been associated with chordoma susceptibility in familial and sporadic chordoma. However, the genetic susceptibility of chordoma remains largely unknown. In this study, we investigated rare germline genetic variants in genes involved in TBXT/chordoma-related signaling pathways and other biological processes in chordoma patients from North America and China. We identified variants that were very rare in general population and internal control datasets and showed evidence for pathogenicity in 265 genes in a whole exome sequencing (WES) dataset of 138 chordoma patients of European ancestry and in a whole genome sequencing (WGS) dataset of 80 Chinese patients with skull base chordoma. Rare and likely pathogenic variants were identified in 32 of 138 European ancestry patients (23%), including genes that are part of notochord development, PI3K/AKT/mTOR, Sonic Hedgehog, SWI/SNF complex and mesoderm development pathways. Rare pathogenic variants in COL2A1, EXT1, PDK1, LRP2, TBXT and TSC2, among others, were also observed in Chinese patients. We identified several rare loss-of-function and predicted deleterious missense variants in germline DNA from patients with chordoma, which may influence chordoma predisposition and reflect a complex susceptibility, warranting further investigation in large studies.
Sections du résumé
BACKGROUND
BACKGROUND
Chordoma is a rare bone cancer with an unknown etiology. TBXT is the only chordoma susceptibility gene identified to date; germline single nucleotide variants and copy number variants in TBXT have been associated with chordoma susceptibility in familial and sporadic chordoma. However, the genetic susceptibility of chordoma remains largely unknown. In this study, we investigated rare germline genetic variants in genes involved in TBXT/chordoma-related signaling pathways and other biological processes in chordoma patients from North America and China.
METHODS
METHODS
We identified variants that were very rare in general population and internal control datasets and showed evidence for pathogenicity in 265 genes in a whole exome sequencing (WES) dataset of 138 chordoma patients of European ancestry and in a whole genome sequencing (WGS) dataset of 80 Chinese patients with skull base chordoma.
RESULTS
RESULTS
Rare and likely pathogenic variants were identified in 32 of 138 European ancestry patients (23%), including genes that are part of notochord development, PI3K/AKT/mTOR, Sonic Hedgehog, SWI/SNF complex and mesoderm development pathways. Rare pathogenic variants in COL2A1, EXT1, PDK1, LRP2, TBXT and TSC2, among others, were also observed in Chinese patients.
CONCLUSION
CONCLUSIONS
We identified several rare loss-of-function and predicted deleterious missense variants in germline DNA from patients with chordoma, which may influence chordoma predisposition and reflect a complex susceptibility, warranting further investigation in large studies.
Identifiants
pubmed: 34070849
pii: cancers13112704
doi: 10.3390/cancers13112704
pmc: PMC8197919
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Bioinformatics. 2009 Jul 15;25(14):1754-60
pubmed: 19451168
Head Neck Pathol. 2018 Jun;12(2):261-268
pubmed: 28980142
Nat Med. 2019 Feb;25(2):292-300
pubmed: 30664779
Cell Rep. 2017 Oct 10;21(2):495-507
pubmed: 29020634
Nucleic Acids Res. 2020 Jan 8;48(D1):D835-D844
pubmed: 31777943
Control Clin Trials. 2000 Dec;21(6 Suppl):251S-272S
pubmed: 11189683
Hum Mol Genet. 2015 Apr 15;24(8):2125-37
pubmed: 25552646
J Neurosurg. 2011 Oct;115(4):760-9
pubmed: 21699479
J Pathol. 2006 Jun;209(2):157-65
pubmed: 16538613
Hum Genet. 2014 Oct;133(10):1289-97
pubmed: 24990759
Hum Genet. 2014 Jan;133(1):1-9
pubmed: 24077912
Neuro Oncol. 2014 Mar;16(3):372-81
pubmed: 24305715
EMBO J. 1995 Oct 2;14(19):4763-72
pubmed: 7588606
Lancet Oncol. 2015 Feb;16(2):e71-83
pubmed: 25638683
Genome Res. 2010 Sep;20(9):1297-303
pubmed: 20644199
Nat Genet. 2009 Nov;41(11):1176-8
pubmed: 19801981
Nat Commun. 2017 Oct 12;8(1):890
pubmed: 29026114
Proc Natl Acad Sci U S A. 2013 May 7;110(19):7922-7
pubmed: 23620515
J Cell Biol. 1998 Nov 30;143(5):1399-412
pubmed: 9832566
J Clin Neurosci. 2014 Sep;21(9):1490-6
pubmed: 24852903
JAMA Oncol. 2020 May 1;6(5):724-734
pubmed: 32191290
Am J Surg Pathol. 2011 Oct;35(10):e47-63
pubmed: 21934399
J Med Genet. 2011 Jul;48(7):444-9
pubmed: 21266383
Nat Genet. 2012 Nov;44(11):1185-7
pubmed: 23064415
Trends Genet. 2019 Jul;35(7):515-526
pubmed: 31128889
Dev Dyn. 2008 Dec;237(12):3953-8
pubmed: 19035356
Bioinformatics. 2009 Aug 15;25(16):2078-9
pubmed: 19505943
J Pathol. 2011 Feb;223(3):327-35
pubmed: 21171078
Am J Hum Genet. 2012 Aug 10;91(2):224-37
pubmed: 22863193
Clin Cancer Res. 2007 Apr 15;13(8):2471-8
pubmed: 17438107
Ann Oncol. 2017 Jun 1;28(6):1230-1242
pubmed: 28184416